{
    "nctId": "NCT02441764",
    "briefTitle": "Halaven Post-Marketing Surveillance (PMS)",
    "officialTitle": "Post-Marketing Surveillance of Halaven Injection in Korean Patients",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 3000,
    "primaryOutcomeMeasure": "Safety of Halaven as a measure of number of participants with adverse events/serious adverse events/adverse drug reactions",
    "eligibilityCriteria": "Participants who are prescribed with Halaven per approved prescribing information of Halaven will be enrolled in the study. This study will be conducted as complete surveillance method; participants who meet the inclusion/exclusion criteria and administrate Halaven for the first time after conclusion of agreement will be enrolled after consent.\n\nInclusion Criteria:\n\nParticipants who meet all of the following criteria will be eligible for inclusion in the study:\n\n1. Participants with following indication: Participants with locally advanced or metastatic breast cancer who have previously received at least two chemotherapeutic regimens which should have included an anthracycline and a taxane.\n2. Participants who have verbal or written consent for use of personal and medical information.\n\nInvestigators will refer to indications regarding inclusion criteria.\n\nExclusion Criteria:\n\n1. Hypersensitivity to the active substance or to any of the excipients\n2. Breast feeding\n3. Pregnancy\n\nInvestigators will refer to indications and contraindications regarding exclusion criteria.",
    "sex": "ALL",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}